Emerging Therapeutics

Rockland’s goals is to produce the analytical tools needed to collect the pharmacodynamic, pharmacokinetic, and toxicology data critical to satisfying regulatory requirements in the process of approval for drugs used in complex therapies, such as biological drugs, cell and gene therapies, and RNA therapeutics (ASOs and siRNAs).

Rockland has a proven track record in producing effective antibodies against various nucleic acid/oligonucleotide targets and modifications, including both modified backbones and nucleosides. In addition to our custom generated anti-oligonucleotide antibodies, we have used our expertise and proprietary technology to create the very first collection of specialty reagent panels that detect common nucleic acid modifications made to oligonucleotide therapeutics, independent of the oligonucleotide sequence and location of the modification.